Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Adhd
Interventions: RELAX; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: ABT-143, simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 129
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Methotrexate, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Coronary Artery Disease, Heart Failure
Interventions: continuous, mechanical ventilatory support; Procedure
Lead sponsor: Aurora BayCare Medical Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Green Bay, Wisconsin

Conditions: Chronic Graft Versus Host Disease, cGVHD
Interventions: Axatilimab, Extracorporeal Photopheresis; Biological · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois

Conditions: Smoking Cessation
Interventions: Empowering Cessation for the ACS South; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions: Lofexidine, Placebo oral tablet; Drug
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 18 Years to 70 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Malignant Neoplasm, Oral Pain, Stomatitis
Interventions: Best Practice, Methylene Blue; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Large-Cell, Diffuse
Interventions: OFATUMUMAB + DHAP, RITUXIMAB + DHAP; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 16
States / cities: Sacramento, California • New Haven, Connecticut • Chicago, Illinois + 12 more

Conditions: Healthy Volunteer
Interventions: PTI-428, Placebo, ethinyl estradiol and levonorgestrel; Drug · Other
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Gastric Foreign Body, Nos, Disorder of Abdomen (Disorder), Foreign Body in Esophagus, Prostatic Diseases, Disease of Small Intestine
Interventions: Natural Orifice Transluminal Endoscopic Surgery (NOTES), Natural Orifice Translumenal Endoscopic Surgery (NOTES); Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infections, Community Acquired Pneumonia
Interventions: Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Long Beach, California • Oakland, California • Orange, California + 10 more

Conditions: Cocaine Use Disorder
Interventions: EMB-001, EMB-001 Placebo; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: San Diego, California • Miami, Florida • Philadelphia, Pennsylvania + 1 more

Conditions: Head and Neck Cancer
Interventions: Retifanlimab, INCAGN02385, INCAGN02390, Placebo; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more

Conditions: Healthy Adult
Interventions: Traditional Hangboard Protocol, Extensor Tendon Isometric Training; Other
Lead sponsor: April Henderson; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions: Fluticasone propionate/salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 51
States / cities: Jonesboro, Arkansas • East Artesia, California • Huntington Beach, California + 45 more

Conditions: Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer
Interventions: Pembrolizumab, GT103; Drug
Lead sponsor: Ryan Dackor; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Detroit, Michigan + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 80
States / cities: Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more

Conditions: Pain, Low Back 'Spine Fusion' Surgery
Interventions: Acupuncture therapies, Control; Procedure
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
Interventions: Lurbinectedin, Irinotecan; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: Santa Monica, California • Boston, Massachusetts • Houston, Texas

Conditions: HIV Infection
Interventions: 3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®)); Behavioral · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 22 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
Interventions: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion; Drug
Lead sponsor: Aptose Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 12 more

Conditions: Obesity, Major Depressive Disorder, Dysthymic Disorder, Cardiovascular Disease
Interventions: Behavior Modification for Weight Loss, Alternative Approach to Weight Loss, Cognitive-Behavior Therapy for Depression, Depression Support and Education; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Sertraline and Elzasonan Combination, Sertraline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Beverly Hills, California • Norwich, Connecticut • New York, New York + 1 more

Search by objective public record fields.

Improving Emotion Regulation in Adolescents With ADHD

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

Study to Determine if Using Ventilation During Open Heart Surgery Improves Lung Outcomes

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

Empowering Cessation ACS South Region

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

Transluminal Flexible Endoscopic Procedure in Foregut and Urologic Surgery

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

The Effects of Finger Extensor Training on Climbing Performance Compared With Traditional Flexor Training

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

'Acupuncture Therapy' for Pain and Function Recovery in Spine Surgery Patients

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)